Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of a clinician reviewing oncology imaging and molecular testing data, reflecting how BIZENGRI’s FDA approval could advance targeted treatment for NRG1 fusion-positive cholangiocarcinoma.
Pharma & Biotech

Why Partner Therapeutics’ BIZENGRI approval matters beyond cholangiocarcinoma

Rare cancer biology is becoming commercially actionable. BIZENGRI’s FDA approval puts NRG1 fusion testing under sharper scrutiny.

Read More
Pharma & Biotech

What Actuate Therapeutics, Inc.’s oral formulation push means for pancreatic cancer drug development economics

Actuate Therapeutics, Inc. is advancing oral elraglusib after FDA IND clearance. Discover what this means for pancreatic cancer economics.

Read More
Representative image: A modern oncology research and strategy setting illustrates Daiichi Sankyo’s DXd antibody drug conjugate expansion plan, as the Japanese drugmaker targets stronger cancer drug leadership through Enhertu, Datroway and its broader 2030 oncology pipeline.
Pharma & Biotech

Why Daiichi Sankyo’s new five-year plan puts oncology at the centre of its next growth phase

Daiichi Sankyo has ADC momentum, but scaling oncology is harder than launching drugs. Its 2030 plan now tests execution, margins and pipeline depth.

Read More
Representative image: A modern dermatology research laboratory scene illustrating Almirall’s Q1 2026 growth momentum, as Ebglyss and Ilumetri strengthen its biologics-led medical dermatology strategy in Europe.
Pharma & Biotech

Can Almirall turn dermatology momentum into a stronger long-term innovation engine?

Almirall’s dermatology engine is growing faster than group sales. The next test is whether biologics and pipeline bets can sustain momentum.

Read More
Representative image: Niagen Bioscience’s investor conference push highlights the growing commercial debate around NAD+ science, healthy aging, Tru Niagen, Niagen Plus, and whether healthspan-focused platforms can convert clinical credibility into durable market confidence.
Pharma & Biotech

Why Niagen Bioscience’s next investor meetings could sharpen the NAD+ market debate

NAD+ is hot, but credibility is scarce. Niagen Bioscience now has to prove healthspan science can support durable investor trust.

Read More
Representative image: A clinician reviews liver imaging in an oncology treatment setting, reflecting Delcath Systems’ liver-directed melphalan strategy for liver-dominant metastatic breast cancer and the growing clinical focus on targeted hepatic cancer therapies.
Pharma & Biotech

Delcath Systems tests whether HEPZATO KIT can move beyond metastatic uveal melanoma

Delcath has a liver-response signal in breast cancer. The harder test is whether HEPZATO KIT can prove value beyond a small cohort.

Read More
Representative image: A clinical research scene showing atopic dermatitis assessment, reflecting TRexBio’s TRB-061 development strategy as TNFR2 agonism and tissue Treg biology emerge as potential new approaches for treating moderate-to-severe inflammatory skin disease.
Pharma & Biotech

Could TRexBio’s Treg bet crack the next big frontier in atopic dermatitis?

Atopic dermatitis has more drugs, but not enough durable control. TRexBio’s TRB-061 tests whether tissue Tregs can change that.

Read More
Representative image: Vistagen’s fasedienol Phase 3 trial highlights the growing search for rapid, as-needed nasal spray treatments for social anxiety disorder, especially in high-pressure public speaking and performance settings.
Pharma & Biotech

Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy

Social anxiety needs faster options. Vistagen’s fasedienol now faces the Phase 3 test that could make or break its nasal-spray thesis.

Read More
Pharma & Biotech

Why Encompass Health is betting on a fast-growing Texas suburb before rivals crowd in

Haslet is growing fast. Encompass Health’s 50-bed rehab hospital shows healthcare real estate is chasing North Texas suburbia.

Read More
Pharma & Biotech

What Saban Community Clinic’s Crenshaw project reveals about urban healthcare deserts

South Los Angeles lacks reliable primary care. Saban Community Clinic’s Crenshaw center tests whether integrated care can close that gap.

Read More